Bioson Pharmaceutical Launches Non-Narcotic Analgesic 'Opirangerin'

On the 25th, Vibozone Pharmaceuticals announced that it has begun full-scale pre-marketing preparations for the non-narcotic analgesic ‘Opirangerin’ (product name Onapraju).

To this end, Vibozone Pharmaceuticals established a new New Drug Marketing Headquarters. Shin Hyun-cheol, appointed as the head of the headquarters, is a marketing expert from Kyungbo Pharmaceuticals who oversaw the launch of the non-narcotic analgesic Maxizec. He was recruited as the director of Vibozone’s Business Development Department in July last year and has been conducting preliminary work for the marketing of Opirangerin.

Additionally, to strengthen communication with global and domestic pharmaceutical companies, Vibozone appointed Hong Seok-cheol, currently the CEO of Vibozone Canada, as the President of Vibozone’s Business Division. President Hong is a global business expert who previously served as the head of business development at Estec Pharma and has experience at Samsung Fine Chemicals (predecessor of Lotte Chemical) and Canada’s Chorney Chemical Company Inc.

Opirangerin is a non-narcotic analgesic in injectable form used for postoperative pain. Vibozone Pharmaceuticals completed Phase 3 clinical trials last year and applied for product approval from the Ministry of Food and Drug Safety (MFDS). According to the company, the approval results from the MFDS are expected within this year. The company expects Opirangerin to be an innovative new drug (First in class) that can resolve various side effects caused by narcotic analgesics.

Lee Doo-hyun, Chairman of the Vibozone Group, stated, “Although narcotic analgesics have become a serious social issue worldwide, narcotic analgesics are still being overused for postoperative pain control in reality. Opirangerin not only has excellent pain reduction effects but also shortens the time required for pain relief, so it is expected to significantly reduce the use of narcotic analgesics.”

He added, “Currently, narcotic analgesics are administered to postoperative pain patients over several days, but our ultimate goal is to reduce this administration period to the day of surgery.”

A Vibozone Pharmaceuticals official said, “Chairman Lee Doo-hyun, who has directly led the development of Opirangerin so far, is leading the efforts by forming a task force with key personnel within the group. Since Opirangerin is an unprecedented innovative new drug, the entire company is putting all its efforts into overall marketing activities from pre-marketing to launch.”